Pila Pharma AB (publ)

PILA.ST

Biotechnology · Healthcare

Price

kr 1.88

+0.18 (+10.59%)

Market Cap

kr 85.9M

Exchange

Stockholm Stock Exchange

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Dec 31, 2025

How the score breaks down

Quality

Weak

Growth

Mixed

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+158.3% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 13.4M (2021) → 34.6M (2025)

Winston Score History

The full picture

Pila Pharma is a small Swedish biotech company focused on developing drugs to treat inflammatory diseases. Its main work centers on a compound called PP001, which is being studied as a potential treatment for conditions like gout and other inflammation-related disorders. The company does not yet sell any approved products and is in the clinical-stage phase of drug development.

Pila Pharma makes no commercial revenue at this point, which explains its deeply negative margins. It is funded primarily through equity raises and operates mainly in Sweden, with a market cap of around $0.1 billion, making it a very small company by global standards. The biggest risk the company faces is typical for clinical-stage bioteckers: it must successfully advance PP001 through clinical trials, secure regulatory approval, and raise enough cash to keep operating — all before generating any real income.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+158.0% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

-15.4% YoY

YoY Growth Rate

Earnings declining

R&D Spend

kr 0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

69.0%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~3 years

kr 16M cash & investments

kr 16M cash & investments at current burn rate

Revenue accelerating

Pila Pharma AB (publ) grew revenue 158% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-878.4%

Thin — -878.4% gross margin

Profit after running costs

Operating Margin

-1429.5%

Losing money on operations — -1429.5%

Return on the money invested

ROCE

-54.3%

Weak — -54.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+42.6%

Fast-growing sales (+42.6% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-588.6%

Burning cash (-588.6%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial